Share Prices & Company Research

Stockbroking

Amryt Pharma

Current Price 122.45p Bid 120.00p Ask 125.00p Change 0.00%
Last Updated: 13/11/2019 15:38. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Amryt Pharma plc's (formerly Fastnet Equity, formerly Fastnet Oil & Gas plc, formerly Sterling Green Group plc, formerly Hamilton Partners plc) is a specialty biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments. The Company holds an exclusive licence to sell Lojuxta (lomitapide) for adults, across the European Economic Area, Middle East and North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body's ability to remove LDL cholesterol ('bad' cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels, leading to aggressive and premature narrowing and blocking of arterial blood vessels. If left untreated, heart attack or sudden death may occur in childhood or early adulthood. Amryt's lead drug candidate, AP101 (Episalvan), is a potential treatment for Epidermolysis bullosa (EB), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. It is currently in Phase 3 clinical trials. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion. Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease.

Financial Highlights Year Ended 31/12/2018

Turnover
£14.45m
Operating Profit
£-15.25m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
-13.06

Key Personnel

Joseph Amrit Wiley
Chief Executive Officer
Rory Peter Nealon
Chief Financial Officer
Harry Thomas Stratford
Non-Executive Chairman
Markus Ziener
Non-Executive Director
Raymond Thomas Stafford
Non-Executive Director
Anthony James Culverwell
Non-Executive Director

Stock Details

EPIC
AMYT
ISIN
GB00BKLTQ412
Shares in Issue
157,718,438
Market cap
£193.21m

Analyst Views (0)

Strong Buy
 
0.00%
Buy
 
0.00%
Hold
 
0.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
122.50p
Bid Price
120.00p
Ask Price
125.00p
Volume
16738
Change Today
0.00p
% Change Today
0.00%
Open
120.00p
Previous Close
122.50p
Intraday High
122.45p
Intraday Low
120.00p
52 Week High
141.00p
52 Week Low
12.13p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Amryt Pharma Intra-day Chart

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Tangible Assets
1.0
1.2
Intangible Assets & Goodwill
52.7
52.6
Investments & Other Non-Current Assets
0.1
0.0
Total Non-Current Assets
53.8
53.8
Inventory
1.9
1.1
Trade & Receivables
5.2
4.7
Cash & Receivables
9.8
20.5
Other Current Assets & Assets Held for Resale
0.0
0.0
Total Assets
70.6
80.1

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Short Term Liabilities
10.5
9.8
Long Term Liabilities
63.4
48.4
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
73.9
58.2

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Net Assets
-3.2
21.9

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Share Capital
21.2
21.2
Minority Interests
0.0
0.0
Retained Earnings
-60.9
-35.1
Share Premium Account
57.3
57.3
Other Equity
-20.9
-21.5
Total Equity
-3.2
21.9

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Cashflow from Operating Activities
-13.1
-11.9
Cashflow Before Financing
-13.3
-12.2
Increase / Decrease in Cash
-10.7
12.2

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Turnover
14.5
12.8
Cost of Sales
5.3
5.4
Gross Profit
9.2
7.4
Operating Profit
-15.3
-14.2
Pre-Tax Profit
-25.7
-26.1
Profit / Loss for the Year
-25.8
-26.1
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.